Introduction {#S1}
============

Severe chronic disorders of consciousness (DOC) after acute coma, which typically resolves within 2 weeks, mainly consist of two subgroups: unresponsive wakefulness syndrome (UWS), previously known as vegetative state (VS), and minimally conscious state (MCS) ([@B1]). VS/UWS is characterized by wakefulness without awareness ([@B2]), whereas MCS is characterized by minimal but definite behavioral evidence of self- or environmental awareness ([@B3]). Recently, MCS has been subcategorized into minimally conscious state minus (MCS−) and minimally conscious state plus (MCS+), based on the level of non-reflexive responsiveness of the patients concerned ([@B4]). MCS− is characterized by non-communicative responses to meaningful stimuli, whereas MCS+ is characterized by command following. This definition is based on the various levels of consciousness retained in different entities and implicates that specific treatment is needed and various prognoses can be expected ([@B5], [@B6]). However, there are still no evidence-based guidelines regarding the treatment of DOC ([@B7]), while neurostimulation techniques have been seen as potential experimental approaches to DOC treatment ([@B8]--[@B10]). As these invasive methods, including deep brain stimulation and spinal cord stimulation, have ethical and procedural limitations ([@B11]), extensive developments have recently been made in approaches that deploy non-invasive brain stimulation (NIBS).

One of these is transcranial magnetic stimulation (TMS), which is a safe, non-invasive, and painless technique that can be applied one stimulus at a time (single-pulse TMS), in pairs of stimuli separated by a variable interval (paired-pulse TMS) or in trains repetitive transcranial magnetic stimulation (rTMS) ([@B12]). When TMS is given repetitively, it has been shown to have a neuro-modulatory effect. Repetitive TMS involves delivery of repeated single-pulse stimulation to specific brain regions ([@B13]) and has been shown to alter cortical excitability, an effect that outlasts the period of the stimulation ([@B14]). Despite intra- and interindividual variability of responses to rTMS ([@B15]), low-frequency rTMS (\~1 Hz) has been shown to reduce cortical excitability, while the high-frequency variety (5--20 Hz) has been demonstrated to increase it ([@B16]). Attempts to use rTMS for DOC treatment have been reported, although the clinical efficacy of this new therapy remains ill defined ([@B17]--[@B21]).

The induced effects of rTMS are related to the site of stimulation, which varied in previous studies. The primary motor cortex (M1) ([@B18]--[@B20]) and the dorsolateral prefrontal cortex (DLPFC) ([@B17], [@B21]) are the most commonly chosen stimulation sites. The rationale has been to improve either motor or cognitive function ([@B22]). The DLPFC is thought to play a central and integrative function for motor control and behavior and is also a critical component of the decision-making network ([@B23]). Meanwhile, magnetic stimulation of the DLPFC has been found to improve learning and memory ([@B24]). Several researchers have chosen the right DLPFC, rather than the left, as the site of stimulation ([@B17], [@B21]). The right DLPFC has been linked to maintenance of sustained arousal and attention, as it has strong connections with the reticular formation ([@B25]), which is similarly relevant for patients with DOC. However, one previous study showed that a single session of 10 Hz rTMS over the right DLPFC did not induce, at group level, any clinical improvement or intra-/intercortical connectivity changes ([@B21]). The left DLPFC area receives visual and somatosensory input from the parietal heteromodal association cortices regarding vision, motion, spatial orientation, and tactile sensations and projects to subcortical, monoaminergic, and cholinergic sources ([@B26]). Previous studies have shown that high-frequency rTMS over the left DLPFC has beneficial effects on the linguistic and cognitive skills of patients with Alzheimer's disease ([@B27]). There is also evidence that rTMS of the left DLPFC could improve major depressive disorder as caused by Parkinson's disease ([@B28]). This approach was also selected in a range of transcranial direct current stimulation studies on DOC patients ([@B22], [@B26]). Based on all the above considerations, we opted to stimulate the left DLPFC in this study.

In this research, we proposed a new stimulation protocol consisting of 10 Hz L-DLPFC rTMS and applied it in patients with VS/UWS or MCS. We aimed to verify whether repeated sessions of 10 Hz rTMS, delivered to the left DLPFC, may produce clinically useful behavioral modifications in DOC patients.

Materials and Methods {#S2}
=====================

Study Participants {#S2-1}
------------------

All participants came from the Department of Neurosurgery, PLA Army General Hospital and were recruited from December 2015 to June 2016. The hospital is one of the major treatment centers for DOC in Beijing. All patients enrolled in this study had been of DOC status for more than 3 months according to the JFK Coma Recovery Scale-Revised (CRS-R) scores, which are widely used to define the level of consciousness and to monitor neurobehavioral recovery in patients. The CRS-R scale is based on six subscales that address the auditory, visual, motor, oromotor/verbal, communication, and arousal processes ([@B29]). All patients recruited in this study received a routine medication and rehabilitation course after admission to hospital. They were monitored closely, and those who were stabilized with no consciousness improvement for 1 month received rTMS protocol in the following month. Patients who showed an obvious increase or decrease in consciousness before rTMS treatment were excluded, as were those who experienced complications such as acute pneumonia during rTMS treatment. Participants with a history of epilepsy, or who had or had had pacemakers, intrathecal baclofen pumps, hydrocephalus shunts, aneurysm clips, electrodes, or other devices implanted were also eliminated. Routine medicine was delivered orally through a nasogastric tube.

Study Design and Stimulation Protocol {#S2-2}
-------------------------------------

After a routine medication and rehabilitation course in the first month of their admission to hospital, all stabilized patients who had no consciousness improvement during said month received active 10 Hz rTMS at the left DLPFC for one session per day over 20 consecutive days (Figure [1](#F1){ref-type="fig"}A). TMS pulses were delivered using a Magstim *R*2 stimulator and an eight-shaped coil (Magstim Company Limited, Whitland, UK), which can produce a biphasic waveform in a pulse width of \~0.1 ms. The coil was placed tangentially toward the scalp over the left DLPFC (position F3 of the 10/20 international electroencephalography system) for active stimulation. Stimulation intensity was determined based on the resting motor threshold (RMT) for each patient, which was defined as the lowest TMS intensity to evoke at least 5 out of 10 EMG with amplitude larger than 50 µV peak-to-peak in the relaxed first dorsal interosseous muscle of the right hand, according to the IFCN Committee recommendations ([@B30]). A single daily session of stimulation consisted of 1,000 pulses (10 Hz trains for 10 s; repeated 10 times with an inter-train interval of 60 s; 11 min and 40 s for total session) at an intensity of 90% RMT (Figure [1](#F1){ref-type="fig"}B). Inserted earplugs, which continuously played a masking noise, were used to prevent the induction of auditory potentials by the click associated with TMS discharge. Bone conduction was attenuated by placing a thin layer of foam between the coil and scalp. Meanwhile, patients' routine medication and rehabilitation courses continued as usual during rTMS treatment.

![**Demonstration of the repetitive transcranial magnetic stimulation (rTMS) protocol**. **(A)** 10 Hz rTMS was delivered at the left dorsolateral prefrontal cortex (DLPFC), lasting for 20 consecutive days. Coma Recovery Scale-Revised scores were assessed at days 1, 5, 10, 15, 20, and 30. **(B)** Illustration of one session: a single daily session of stimulation consisted of 1,000 pulses; 10 s as one train; 10 trains as one session, interrupted with an interval of 60 s; 11 min and 40 s for one session.](fneur-08-00182-g001){#F1}

Outcome Measures {#S2-3}
----------------

Clinical evaluations using the CRS-R were performed at five different time points during and after rTMS treatment, including at days 5, 10, 15, and 20, with the final assessment being on day 30, 10 days after completion of the rTMS protocol (Figure [1](#F1){ref-type="fig"}A). All CRS-R assessments were undertaken by a single trained clinician who was blinded to this study.

The Clinical Global Impression-Improvement (CGI-I) scale ([@B31]) was applied on day 30 by family members who had been assisting their relatives at the bedside for at least 3 months. It is commonly used as an outcome measure in studies that are evaluating the efficacy of medical treatments (CGI-I score interpretation: 1 = much improved, 2 = improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = worse, 7 = much worse).

Side effects were also monitored during the study, including seizure induction and scalp burns.

Statistics {#S2-4}
----------

The Mann--Whitney *U* test was used to compare the baseline consciousness between the two groups of patients, while the Wilcoxon signed-rank test was deployed to analyze the therapeutic effects of our treatment protocol. *p* \< 0.05 was recognized as significant. Spearman's rank correlation coefficient was calculated to assess the correlation between the CRS-R scale and the CGI-I measurements.

Results {#S3}
=======

This study featured a total of 41 DOC patients, who were hospitalized in the ward where we conducted our investigations from December 2015 to June 2016. During their routine medication and rehabilitation course in the first month of their admission, 16 patients remained in a stable clinical state and displayed no consciousness improvement. Eventually, all of these (ranging from 23 to 67 years old, including five women,) completed the study. There was no focal lesion in the left DLPFC in any of said participants, as evidenced by the brain scans. Detailed demographic and clinical characteristics of these patients are reported in Table [1](#T1){ref-type="table"}. Based on the CRS-R scores, 5 patients were classified as MCS and the other 11 as VS/UWS.

###### 

**Demographic and clinical characteristics of all the DOC patients included in the study**.

  Patient   Sex   Age   Etiology       Duration (months)   CRS-R   Diagnosis   Treatment                          
  --------- ----- ----- -------------- ------------------- ------- ----------- ----------- --- --- --- --- ------ ----------------------
  P1        M     23    TBI            13                  1       0           3           1   0   2   7   MCS−   Amantadine, Baclofen
  P2        F     47    Stroke (ICH)   6                   1       1           3           1   0   2   8   MCS−   Amantadine
  P3        F     31    Anoxia         35                  2       2           2           1   0   2   9   MCS−   Amantadine
  P4        M     44    Stroke (ICH)   3                   1       3           2           1   0   2   9   MCS−   Amantadine, Baclofen
  P5        M     47    Stroke (ICH)   3                   0       2           2           1   0   2   7   MCS−   Amantadine
  P6        M     67    Stroke (ICH)   4                   1       1           2           1   0   0   5   VS     Amantadine, Baclofen
  P7        F     26    Stroke (ICH)   4                   1       0           2           1   0   2   6   VS     Amantadine, Baclofen
  P8        M     39    Stroke (ICH)   4                   1       1           2           1   0   2   7   VS     Amantadine, Baclofen
  P9        M     40    TBI            16                  1       0           2           1   0   2   6   VS     Amantadine, Baclofen
  P10       M     27    Stroke (ICH)   11                  0       0           2           1   0   1   4   VS     Amantadine
  P11       M     52    Stroke (ICH)   4                   1       1           2           1   0   0   5   VS     Amantadine
  P12       M     60    Anoxia         3                   1       0           2           1   0   2   6   VS     Amantadine, Baclofen
  P13       M     42    Stroke (CI)    6                   1       1           2           1   0   2   7   VS     Amantadine
  P14       M     35    Anoxia         3                   0       0           2           1   0   2   5   VS     Amantadine
  P15       F     51    Anoxia         6                   1       0           2           1   0   2   6   VS     Amantadine, Baclofen
  P16       F     50    Anoxia         8                   1       0           2           1   0   2   6   VS     Amantadine, Baclofen

*Duration: time at which the patient has been in a disorder of consciousness; diagnosis: CRS-R categorization at the time of recruitment*.

*Gray shades were used to distinguish between VS and MCS group patients*.

*CRS-R, Coma Recovery Scale-Revised; VS, vegetative state; ICH, intracerebral hemorrhage; CI, cerebral infarction; MCS, minimally conscious state; F, female; M, male; A, auditory; V, visual; M, motor; OM, oromotor; C, communication; Ar, arousal; DOC, disorders of consciousness*.

Effects of the 10 Hz rTMS Treatment Protocol As Measured by CRS-R at Day 30 {#S3-1}
---------------------------------------------------------------------------

A total of 16 patients with chronic DOC (5 MCS and 11 VS/UWS) completed the treatment (Table [1](#T1){ref-type="table"}; Figure [1](#F1){ref-type="fig"}), with no specific side effects observed. At day 30, a significant increase in the CRS-R scores was observed compared to the baseline in all participants (Figure [2](#F2){ref-type="fig"}A, *p* = 0.007). Specifically, diagnoses were changed in five patients, based on their CRS-R scores (Table [2](#T2){ref-type="table"}). We also analyzed said scores separately based on the baseline diagnosis and found significant improvement in the MCS patients (*p* = 0.042) rather than in their VS/UWS counterparts (*p* = 0.066) (Figures [2](#F2){ref-type="fig"}B,C).

![**Effects of repetitive transcranial magnetic stimulation treatment evaluated with Coma Recovery Scale-Revised (CRS-R) in both minimally conscious state (MCS) and VS/UWS patients**. Significant improvement is shown in the entire group \[**(A)**, *p* = 0.007\]. However, subgroup analysis of the therapeutic effects at each time point only revealed significant differences in the MCS patients \[**(B)**, *p* = 0.042\], and significant improvement was first shown at day 10 \[**(B)**, *p* = 0.041\]. In the VS/UWS patients, there was no significant improvement in CRS-R scores \[**(C)**, *p* = 0.066\]. Data are displayed as the box--whiskers graphs, with the whiskers representing the minimum and maximum of the datasets.](fneur-08-00182-g002){#F2}

###### 

**Clinical evaluation of the DOC patients at day 30**.

  Patient   CRS-R improvement   Change of diagnosis                          
  --------- ------------------- --------------------- --- --- --- --- ------ -------------------------
  P1        0                   2                     0   0   0   0   2(+)   Remained MCS−
  P2        3                   2                     0   0   0   0   5(+)   MCS− elevated to MCS+
  P3        0                   1                     1   0   0   0   2(+)   Remained MCS−
  P4        1                   0                     0   0   0   0   1(+)   Remained MCS−
  P5        3                   0                     0   0   0   0   3(+)   MCS− elevated to MCS+
  P6        0                   0                     0   0   0   0   0      Remained VS/UWS
  P7        0                   0                     0   0   0   0   0      Remained VS/UWS
  P8        2                   0                     1   0   0   0   3(+)   VS/UWS elevated to MCS+
  P9        0                   0                     0   0   0   0   0      Remained VS/UWS
  P10       0                   0                     0   0   0   0   0      Remained VS/UWS
  P11       0                   0                     0   0   0   0   0      Remained VS/UWS
  P12       0                   0                     0   0   0   0   0      Remained VS/UWS
  P13       0                   0                     1   0   0   0   1(+)   VS/UWS elevated to MCS−
  P14       1                   0                     0   0   0   0   1(+)   Remained VS/UWS
  P15       2                   0                     0   0   0   0   2(+)   VS/UWS elevated to MCS+
  P16       0                   0                     0   0   0   0   0      Remained VS/UWS

*Gray shades were used to distinguish between VS and MCS group patients*.

*A, auditory; V, visual; M, motor; OM, oromotor; C, communication; Ar, arousal; DOC, disorders of consciousness; CRS-R, Coma Recovery Scale-Revised; MCS, minimally conscious state*.

Specific Clinical Manifestations Related to CRS-R Score Elevation {#S3-2}
-----------------------------------------------------------------

The CRS-R scores were increased in all five MCS patients. P1 had a baseline CRS-R score of 7; his score increased because he recovered the ability to visually pursue his own reflection in a moving mirror; the patient's status remained as MCS−. P2 had a baseline CRS-R score of 8. Accompanied by stimulation, the consciousness level of the patient rose from MCS− to MCS+, while the CRS-R score was elevated from 8 to 13. P3 had a baseline CRS-R score of 9, which finally increased to 11. This augmentation was based on the participant's ability to localize noxious stimulation and visually pursue bright images on a mobile phone screen. Moving on to P4, this patient had a baseline CRS-R score of 9, which increased slightly to 10 as he recovered the ability to localize sound. P5, meanwhile, had a baseline CRS-R score of 7, which was boosted to 10 as a result of the participant regaining the faculty of following commands reproducibly; the subject was then diagnosed as MCS+.

Turning to the other group, the CRS-R scores increased in 4 of 11 VS/UWS patients. First, P8 had a baseline CRS-R score of 7. His score increased to 10 due to improvement in auditory and motor function, including the ability to localize noxious stimulation and follow commands reproducibly; consequently, his status was improved to MCS+. P13 also had a baseline CRS-R score of 7, which was nudged up to 8 as he regained the ability to pinpoint noxious stimulation; the patient's status was elevated to MCS−. P14, meanwhile, had a baseline CRS-R score of 5, which rose slightly to 6 due to an improvement in his auditory scale; his status remained as VS/UWS. Finally, P15 had a baseline CRS-R score of 6. This increased to 8, as she recovered the ability to follow commands reproducibly; her status was redefined as MCS+.

Onset Time of the Therapeutic Effect in the MCS Patients {#S3-3}
--------------------------------------------------------

We analyzed the CRS-R scores at all time points and found that day 10 was the earliest point at which we could observe a significant improvement in the MCS patients (*p* = 0.041) (Figure [2](#F2){ref-type="fig"}B). However, the patients stabilized and no significant improvement was observed after day 10.

CGI-I Evaluations by Caregivers and Correlation between the CRS-R Scores and CGI-I Scores {#S3-4}
-----------------------------------------------------------------------------------------

Clinical Global Impression-Improvement scores were listed (Figure [3](#F3){ref-type="fig"}A). We found similar results from both scales in all patients in terms of improvement posttreatment (Figure [3](#F3){ref-type="fig"}B). In addition, correlation analysis showed good correlation between the CRS-R and CGI-I scores (Spearman's *r* = 0.9191) (Figure [3](#F3){ref-type="fig"}C).

![**(A)** The Clinical Global Impression-Improvement (CGI-I) scores of all 16 participants are listed. **(B)** CGI-I evaluations and the Coma Recovery Scale-Revised (CRS-R) score elevation at day 30. **(C)** Good concordance was seen between the results of the two rating scales (Spearman's *r* = 0.9191).](fneur-08-00182-g003){#F3}

Discussion {#S4}
==========

This clinical study demonstrated that 10 Hz multisession rTMS applied to the left DLPFC could produce beneficial behavioral modifications, as tested by the CRS-R and CGI-I scales in DOC patients, without observable side effects. MCS patients may benefit more from this treatment than VS/UWS patients on a group level.

As a representative of NIBS approaches, TMS has attracted increasing attention in the DOC research field. There is an emerging possibility of using rTMS in an attempt to treat DOC patients, with some studies reporting encouraging results ([@B17], [@B18], [@B21]). Louise-Bender Pape et al. ([@B17]) reported a trend toward significant neurobehavioral gains that were temporally related to patterned rTMS of the right DLPFC in a traumatic VS/UWS patient. Piccione et al. ([@B18]), meanwhile, reported an arousal with transient increase of meaningful behaviors in an MCS patient following a single session of 20 Hz rTMS of the M1. Finally, Naro et al. ([@B21]) demonstrated that a single session of 10 Hz rTMS over the right DLPFC may transiently improve consciousness and partially restore the connectivity within several cortical areas, based on positive results in 3 of 10 postanoxic VS/UWS patients. However, there have also been reports of negative results ([@B19], [@B20]). An uncontrolled study performed by Manganotti et al. ([@B19]) found no clinical modifications in three VS and two MCS patients using the rTMS paradigm of Piccione et al. ([@B18]), while long-lasting behavioral and neurophysiological modifications were observed in only one MCS patient with rTMS over M1. Elsewhere, a randomized, sham-controlled study performed by Cincotta et al. ([@B20]) showed no effects of 20 Hz rTMS on the primary motor cortex in VS patients. Another confounding factor is that among all the studies reported, stimulation protocols varied widely. There is no specific, unified criterion regarding rTMS for DOC treatment. Therefore, its clinical application still requires deep investigation.

We designed our stimulation protocol on the basis of full consideration and a literature review. In addition to the stimulation site mentioned earlier, stimulation frequency and duration may also be relevant to the final effect. Low-frequency rTMS can induce inhibition in neural activity, while the high-frequency variety can activate neurons ([@B32], [@B33]). Seizure induction after 20 Hz rTMS stimulation was applied to the DLPFC had been reported earlier ([@B34]). No adverse events were caused in participants in a single-session 10 Hz DLPFC rTMS study. Given the current level of evidence regarding rTMS for DOC, and taking safety considerations into account, we chose 10 Hz as the effective stimulation frequency. Naro et al. ([@B21]) demonstrated that a single session of 10 Hz rTMS brought a significant, but transient, clinical improvement in only 3 of 10 VS/UWS patients in a similar study. Just one session may not be sufficient for a treatment protocol. The protocol used in this study was a revision based on Naro's study ([@B21]); we used 20 sessions, rather than just 1, to verify the accumulation efficacy of the rTMS. A multisession protocol seems more effective than that with only one session. However, it is not certain that the effect will remain at the same level over prolonged treatment. In the current study, significant improvement was first shown at day 10, while no significant improvement was noticed after that date in the MCS set. The duration of the stimulation protocol will require further exploration.

While repetitive TMS has been administered to DOC patients for some time, there is insufficient evidence to formulate recommendations regarding their use in clinical practice ([@B1]). An obvious study difficulty is how to disentangle variations related to natural recovery or other treatment from rTMS-induced changes. The strongest design for supporting our hypothesis would be a parallel group design wherein some subjects receive sham treatment and others real treatment. However, the etiologies and clinical statuses are highly heterogeneous among DOC patients. There are logistical and methodological difficulties associated with conducting placebo-controlled trials in this population ([@B35]), especially with limited subjects. We used a self-controlled study before and after rTMS treatment. Restrictions were imposed on the selection criteria of participants in an attempt to minimize interference with natural recovery. All measures were taken to improve the credibility of the results. Although the study design was far from ideal, the results still gave us many meaningful pointers.

Our study illustrates the residual capacity for neural plasticity and recovery of consciousness in some DOC patients. If we separate VS/UWS and MCS as two groups, the curative effect observed is significantly different between them. MCS patients can attain more benefit from rTMS on a group level. This is in line with previous studies that showed greater capacity for neural plasticity in patients in MCS ([@B22], [@B36], [@B37]). However, it is worth noting that a minority of our VS/UWS patients also improved behaviorally, with three even being elevated to MCS. This implies that neural networks are capable of reacting as an efficient substrate for the remote effects of rTMS, which were also retained in at least some VS/UWS participants. The degree of disturbance of consciousness is more like a continuous spectrum, and there may be no absolute discernible boundaries between VS/UWS and MCS. The reasons for the negative results of the current rTMS trial in other VS/UWS patients are complicated; they may be related to a much more severe impairment of functional cortical connectivity in VS/UWS. Another hypothesis is that the rTMS intensity employed may have been too low. Perhaps in some situations, cortical connectivity is completely (or almost completely) destroyed, so that rTMS can cause no reaction. It is also reasonable to speculate that in certain patients, cortical connectivity is retained to some extent. While it is possible that higher rTMS intensity could produce some effect, this has not yet been verified. Further investigations are required.

To the best of our knowledge, although the sample size was still very small, this was the first study for DOC therapy to suggest that rTMS over DLPFC may induce clinical improvement at group level; it also involved more subjects than previous reports. Some of the latter were case reports, with only one patient discussed ([@B17], [@B18]). The numbers of subjects in other previous studies were all very small. For example, Manganotti et al. ([@B19]) included three VS and three MCS patients, finding long-lasting behavioral and neurophysiological modifications in only one MCS subject. Naro et al. ([@B21]) included 10 postanoxic VS/UWS patients and found a significant, but transient, clinical improvement in only 3. Meanwhile, Cincotta et al. ([@B20]) included 11 VS/UWS patients and reported a negative result. Our study included 5 MCS and 11 VS/UWS participants, and we found that 4 and 5 improved respectively. In addition, the effect of the current stimulation protocol appears more definite when compared with previous studies. We found statistically significant results, especially for MCS patients. Although a series of treatments are routinely administered for DOC patients, few interventions have been rigorously shown to be effective ([@B38]). To date, the evidence has been insufficient to make rTMS---an established method for DOC patients in clinical practice ([@B1]). Although our preliminary results still could not be used to formulate a recommended, specific and unified criterion regarding rTMS for DOC treatment, they add evidence to the case for rTMS as an effective method of neurorehabilitation. As the effect of this multisession protocol appeared to be better than that of only one session, the accumulation efficacy of rTMS has been partly verified. The long-term effect needs to be verified to determine its clinical and practical value in future work. Extended follow-up time and prolonged or repeated stimulation should be considered. A larger study with controlled subjects, which meets rigorous inclusion and exclusion criteria and follows a carefully defined protocol using several methods of evaluating consciousness, both global and specific, would be needed.

Conclusion {#S5}
==========

We demonstrated that 10 Hz multisession rTMS applied to the left DLPFC seems promising for the rehabilitation of patients with severe DOC. Beneficial effects were observed in all MCS patients, and some VS/UWS patients, at the individual level. Significant improvement was found in the former, rather than the latter, at group level. Due to the relatively small sample size, patients in this study were not subdivided and discussed according to brain injury etiology. We cannot confidently state that an optimal stimulation protocol has been found and confirmed for DOC treatment. Further studies are needed to verify the clinical effect of rTMS on larger numbers of patients. The implication of brain injury etiology for rTMS treatment could also be studied.
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